iTeos Therapeutics
Cambridge, US · Founded 2019 · Delaware corporation · 2 known investors
Targets the tumor microenvironment to strengthen immune cell efficacy in eradicating cancer.
Founders & leadership
DH
David HallalDirector
MD
Michel DetheuxExecutive Officer, Director
PB
Priyanka BelawatDirector
AG
Ansbert GadickeDirector
TV
Tim Van HauwermeirenDirector
CB
CHris BuyseDirector
JS
Jonathan SkipperDirector
DB
Detlev BiniszkiewiczDirector
Investors · 2
Reported raises · per SEC filings
Form D private placements▶$125.4MraisedApr 2020 · 36 investors · Other TechnologyRule 506(b)
▶$125.4MraisedApr 2020 · 36 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- David HallalDirector
- Detlev BiniszkiewiczDirector
- Michel DetheuxExecutive Officer, Director
- Priyanka BelawatDirector
- Ansbert GadickeDirector
- Tim Van HauwermeirenDirector
- CHris BuyseDirector
- Jonathan SkipperDirector
- Offering amount
- $125.4M
- Amount sold
- $125.4M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.